Nantes

• A First-in-Human Dose Escalation Study of JNJ-79635322, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated A … Recruiting
  2023-503679-12-00 1 2022-11-21 Relapsed or Refractory Multiple Myeloma
• A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting
  2024-514180-25-00 5 2022-11-21 unresectable or metastatic HER2+ colorectal cancer
• MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex … Recruiting
  2024-514139-50-00 5 2022-11-14 Multiple myeloma
• VANCALLO - Prevention of C. difficile infections by oral vancomycin in patients treated for allogeneic hematopoietic stem cell transplantati … Recruiting
  2024-513490-45-00 5 2022-10-27 Patients hospitalized for allogeneic hematopoietic stem cell transplan
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination … Recruiting
  2023-503442-30-00 5 2022-10-14 Multiple Myeloma
• ASPIC - Antimicrobial Stewardship for Ventilator Associated Pneumonia in Intensive Care Recruiting
  2024-513327-16-00 5 2022-09-20 Intensive care
• CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomics Recruiting
  2022-500295-60-00 4 2022-09-15 Acute Myeloid Leukemia
• MetroWilms Recruiting
  2022-502687-20-00 4 2022-09-14 Wilms tumor
• Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel Recruiting
  2023-505530-10-00 6 2022-09-14 Multiple Myeloma
• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia … Recruiting
  2023-510384-36-00 5 2022-09-13 Newly Diagnosed Multiple Myeloma
• Baricitinib in patients with relapsing or naïve dermatomyositis (BIRD) Recruiting
  2024-511899-32-00 10 2022-08-31 Dermatomyositis; Baricitinib in patients with relapsing or naïve derma
• A Phase 3 Study Comparing Pirtobrutinib to Ibrutinib in CLL/SLL Recruiting
  2023-507699-38-00 5 2022-08-30 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• Intravenous Immunoglobulins for Prevention of BKV Viremia in Kidney Transplant Recipients According to BKV genotype-specific Neutralizing An … Recruiting
  2024-515243-37-00 11 2022-08-21 Kidney Transplantation BKV infection
• A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple M … Recruiting
  2023-506247-42-00 3 2022-08-17 Relapsed/Refractory Multiple Myeloma
• This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin … Recruiting
  2023-505347-38-00 9 2022-06-13 B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma
• A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to … Recruiting
  2024-515354-24-00 9 2022-05-18 Low risk myelodysplastic syndrom without RS having failed or being ine
• Fecal Microbiota Transplantation in the prevention of complications after allogeneic hematopoietic stem cell transplantation for hematologic … Recruiting
  2024-512969-14-01 4 2022-05-02 Patient who underwent Allogeneic hematopoietic stem cell transplantati
• A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) afte … Recruiting
  2024-515945-40-00 10 2022-05-02 Non small cell lung cancer
• A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1) Recruiting
  2024-511793-71-00 7 2022-02-28 Advanced ROS1-positive NSCLC and other advanced ROS1-positive solid tu
• Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants with Myotonic Dystrophy Type 1 Recruiting
  2023-510353-42-00 7 2022-02-21 Myotonic Dystrophy Type 1
• API-AHAI - Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a P … Recruiting
  2024-513191-17-00 4 2022-02-03 autoimmune hemolytic anemia
• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituxim … Recruiting
  2024-510690-16-00 5 2022-01-31 Relapsed/refractory follicular lymphoma
• STUDY TO ASSESS THE SCHEMAS OF RETREATMENT WITH LUTATHERA® IN PATIENTS WITH NEW PROGRESSION OF INTESTINAL WELL-DIFFERENTIATED NEUROENDOCRINE … Recruiting
  2024-511001-28-00 4 2021-12-13 Neuroendocrine tumor
• Multicenter randomized two arms study evaluating the efficacy of prophylactic Rituximab in EBV negative kidney transplant recipients on inci … Recruiting
  2024-515075-36-00 6 2021-12-01 kidney transplantion -Epstein Barr virus

Showing 385–408 of 787 trials